Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 462 of 5804
-
RNA vaccine fights childhood cancers in new trial
Disease control OngoingThe Investigators have demonstrated in preclinical studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine …
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy duo aims to shrink stomach tumors before surgery
Disease control Recruiting nowTo explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate …
Phase: PHASE2 • Sponsor: Shandong Provincial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New TB cocktails aim to speed up recovery
Disease control Recruiting nowA5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New lung cancer combo aims to outperform current standard in consolidation therapy
Disease control Recruiting nowThis is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evalu…
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to stop Triple-Negative breast cancer recurrence
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy associated with pem…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Blood test may spot lung cancer without a needle biopsy
Diagnosis Recruiting nowInvestigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the p…
Sponsor: National Taiwan University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New study aims to prevent suicide in vulnerable teens
Knowledge-focused Recruiting nowSuicide is one of the main causes of death among teenagers. Because it is preventable, primary prevention of suicide has become a public health priority, with encouraging results in promoting suicide awareness and reducing suicidal thoughts among adolescents. However, the lack of…
Phase: NA • Sponsor: Stephanie Baggio • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy aims to supercharge immune cells against tough melanoma
Disease control Recruiting nowA Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Off-the-Shelf cell therapy takes on tough lymphoma
Disease control Recruiting nowThis is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill could stop Period-Linked migraines before they start
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowResearchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New gout drug shows promise in major trial
Disease control OngoingThis study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Phase: PHASE3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy aims to stop cervical cancer return
Disease control Recruiting nowEfficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Phase: PHASE2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
⭐️ VACCINE ⭐️ OngoingThis phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of …
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC
-
Promising new radiation therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental cell therapy takes aim at stubborn blood cancers
Disease control Recruiting nowThis study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) …
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
No-Implant shunt could ease heart failure burden
Disease control ENROLLING_BY_INVITATIONProspective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.
Phase: NA • Sponsor: Alleviant Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough brain tumors: targeted radiation trial launches
Disease control Recruiting nowNovel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation. The LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision …
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to boost liver cancer treatment
Disease control Recruiting nowThis single-center, prospective phase II clinical trial evaluates the safety and therapeutic efficacy of combining carbon ion radiotherapy with the standard first-line regimen of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. The study aims to de…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill could shrink spleen and lymph nodes in rare ALPS disease
Disease control Recruiting nowBackground: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatme…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC